Samchandang Pharm 2026: The Era of Billion-Dollar Royalties and Global Platform Validation

 

Viewing Samchandang Pharm (000250) merely as an ophthalmic specialist is a mistake that could lead to missing a massive opportunity in 2026. This is the year when the seeds planted by the company finally bear fruit in the form of substantial cash flow. We analyze the core drivers—specifically the dominance in the European market and the commercial value of its oral formulation technology.

1. SCD411 (Eylea Biosimilar): The Economic Value of "Exclusive" European Rights

The cornerstone of Samchandang’s 2026 performance is the European market. Investors must pay close attention to the "Profit Share" model rather than simple revenue figures.

• Maximizing Operating Margins: The contract structure with European partners is not a simple commission-based deal. Instead, it is a high-margin business where Samchandang receives up to 50% of the net profit as royalties. Most of this income flows directly to the bottom line after manufacturing costs.

• PFS (Pre-Filled Syringe) Patent Barrier: While the original Eylea requires manual transfer from a vial to a syringe, Samchandang leads with a PFS formulation. This superior convenience is a strategic weapon to capture the #1 market share among biosimilars in Europe by 2026.

• Projected Cash Inflow: Market consensus suggests that milestone payments and royalties from Europe, Canada, and other regions could exceed hundreds of billions of KRW in 2026 alone.

2. S-PASS Platform: A Dark Horse in the "Oral GLP-1 (Obesity)" Market

2026 will be the landmark year when Samchandang’s S-PASS (Oral Drug Delivery Platform) expands beyond insulin into the GLP-1 (Obesity/Diabetes) market.

• Converting Ozempic/Wegovy to Oral Forms: Currently, the global obesity market is dominated by injectables. Samchandang is in discussions with Global Big Pharma for Joint Development and Licensing-Out (L/O) to convert these into pill forms.

• Technology Scalability: As clinical data for Oral Insulin (SCD0503) becomes visible in 2026, global partnerships regarding GLP-1 formulations are expected to materialize. This technology will serve as the primary trigger for "Valuation Re-rating," transforming Samchandang from a traditional pharma company into a Global Biotech Platform.

3. 2026 Financial Outlook: Proving "Dreams" with "Numbers"

The financing risks that previously concerned investors are expected to be fully resolved by 2026.

• Free Cash Flow (FCF) Inflection Point: Having passed the stage of heavy R&D expenditure, the company is entering a phase of significant royalty inflows. The 2026 operating profit is projected to grow by several hundred percent compared to historical averages.

• Shareholder Returns: The massive cash reserves will provide the financial flexibility for dividends or share buybacks, further enhancing shareholder value.

4. Final Verdict: "Break the Bio-Industry Stereotypes"

While many K-Bio stocks rely on the hope of "clinical success," Samchandang Pharm in 2026 will respond with the reality of "Global Commercial Profits." With the market capture of Eylea biosimilars and the global expansion of the S-PASS platform, Samchandang Pharm is a "Must-Have Bio Blue-Chip" for any serious portfolio.

Investment decisions and responsibilities rest with the individual.

Thank you for reading.

Skyblue Shirt Soobin (하늘색셔츠 수빈)

March 30, 2026 Update | Samchandang Pharm Strategic Report

---

💡 Sources & References

• Samchandang Pharm Quarterly/Annual Reports & Official IR Books (2024-2026)

• Global Biosimilar Market Outlook (EvaluatePharma)

• KRX (Korea Exchange) Bio Sector Disclosure Data

• Integrated Equity Research from Major Investment Banks (NH, Samsung, Mirae Asset, etc.)